NasdaqGS:GILDBiotechs
Should First-Line Trodelvy Breast Cancer Approvals Reshape the Gilead Sciences (GILD) Investment Narrative?
In late June 2026, Gilead Sciences reported that the FDA and European Commission approved Trodelvy for first-line treatment of unresectable locally advanced or metastatic triple-negative breast cancer, backed by Phase 3 ASCENT-03 and ASCENT-04 data showing clinically meaningful progression-free survival advantages over chemotherapy-based regimens.
These decisions elevate Trodelvy’s role in HER2-negative breast cancer care, potentially expanding its use across PD-L1 statuses and reinforcing...